Intriguingly, a switch in pathway dependence has been observed from PI3K/AKT to MEK/ERK in advanced HER2+ BC, leading to resistance to anti-HER2 therapies, and making this type of cancer sensitive to MEK/ERK inhibitors [43]. The gene discussed is MAP2K7; the disease is cancer.